JP7143295B2 - ピペリジン－２，６－ジオン誘導体及びクローン病の治療 - Google Patents
ピペリジン－２，６－ジオン誘導体及びクローン病の治療 Download PDFInfo
- Publication number
- JP7143295B2 JP7143295B2 JP2019528110A JP2019528110A JP7143295B2 JP 7143295 B2 JP7143295 B2 JP 7143295B2 JP 2019528110 A JP2019528110 A JP 2019528110A JP 2019528110 A JP2019528110 A JP 2019528110A JP 7143295 B2 JP7143295 B2 JP 7143295B2
- Authority
- JP
- Japan
- Prior art keywords
- dione
- pharmaceutically acceptable
- acceptable salts
- isoindoline
- dioxopiperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611041317 | 2016-11-24 | ||
| CN201611041317.5 | 2016-11-24 | ||
| PCT/CN2017/112669 WO2018095378A1 (zh) | 2016-11-24 | 2017-11-23 | 哌啶-2,6-二酮衍生物以及克罗恩氏病的治疗 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500204A JP2020500204A (ja) | 2020-01-09 |
| JP2020500204A5 JP2020500204A5 (enExample) | 2020-08-20 |
| JP7143295B2 true JP7143295B2 (ja) | 2022-09-28 |
Family
ID=62194806
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528110A Active JP7143295B2 (ja) | 2016-11-24 | 2017-11-23 | ピペリジン－２，６－ジオン誘導体及びクローン病の治療 |
| JP2019528114A Active JP7143296B2 (ja) | 2016-11-24 | 2017-11-23 | ピペリジン－２，６－ジオン誘導体及び潰瘍性結腸炎の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528114A Active JP7143296B2 (ja) | 2016-11-24 | 2017-11-23 | ピペリジン－２，６－ジオン誘導体及び潰瘍性結腸炎の治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US11485724B2 (enExample) |
| EP (2) | EP3546450A4 (enExample) |
| JP (2) | JP7143295B2 (enExample) |
| CN (2) | CN108101887A (enExample) |
| AU (2) | AU2017366514B2 (enExample) |
| CA (2) | CA3049161C (enExample) |
| WO (2) | WO2018095377A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018095377A1 (zh) | 2016-11-24 | 2018-05-31 | 天津和美生物技术有限公司 | 哌啶-2,6-二酮衍生物以及溃疡性结肠炎的治疗 |
| CN108727319A (zh) * | 2018-09-05 | 2018-11-02 | 常州大学 | 一种3-硝基邻苯二甲酸酐的制备方法 |
| CN109293631B (zh) * | 2018-11-30 | 2020-05-08 | 常州制药厂有限公司 | 3-氨基-n-(2，6-二氧代-3-哌啶基)-邻苯二甲酰亚胺化合物的制备方法 |
| GB202002926D0 (en) * | 2020-02-28 | 2020-04-15 | Benevolentai Tech Limited | Compositions and uses thereof |
| CN111320604B (zh) * | 2020-04-22 | 2021-02-09 | 牡丹江医学院 | 一种治疗小儿口腔黏膜疾病的化合物、制备方法及其用途 |
| CN118370746A (zh) * | 2024-04-25 | 2024-07-23 | 江苏省中医院 | 马尿酸在制备溃疡性结肠炎治疗药物中的应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002070480A1 (es) | 2001-03-01 | 2002-09-12 | Fundacion Universitaria San Pablo Ceu | Derivados de glutarimida como agentes terapeuticos |
| CN1961876A (zh) | 2005-11-08 | 2007-05-16 | 北京恩华医药研究院 | 邻苯二甲酰亚胺衍生物在制备抗新血管生成的药物中的用途 |
| JP2008534631A (ja) | 2005-04-07 | 2008-08-28 | 天津和美生物技▲術▼有限公司 | 細胞の腫瘍壊死因子釈放を抑制できるピペリジン−２，６−−ジオン誘導物 |
| JP4703554B2 (ja) | 2003-03-27 | 2011-06-15 | 天津和美生物技術有限公司 | 水溶性のサリドマイド誘導体 |
| JP2013535009A (ja) | 2010-06-18 | 2013-09-09 | 大鵬薬品工業株式会社 | Ｐｒｐｋ−ｔｐｒｋｂモジュレーター及びその使用 |
| JP2020500205A (ja) | 2016-11-24 | 2020-01-09 | 天津和美生物技術有限公司 | ピペリジン−２，６−ジオン誘導体及び潰瘍性結腸炎の治療 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1336602A1 (en) * | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
| CA2808646C (en) * | 2003-09-17 | 2016-08-23 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Thalidomide analogs as tnf-alpha modulators |
| BRPI0607239A2 (pt) | 2005-01-25 | 2009-08-25 | Celgene Corp | usos de uma quantidade terapeuticamente ou profilaticamente eficaz de 4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol-1,3-d iona, de (3r)-4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol- 1,3-diona, e de (3s)-4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol- 1,3-diona, ou um sal ou solvato farmaceuticamente aceitável das mesmas, composição farmacêutica, e, forma de dosagem unitária simples |
| EP2981262A1 (en) | 2013-04-02 | 2016-02-10 | Celgene Corporation | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
-
2017
- 2017-11-23 WO PCT/CN2017/112668 patent/WO2018095377A1/zh not_active Ceased
- 2017-11-23 EP EP17874499.1A patent/EP3546450A4/en active Pending
- 2017-11-23 US US16/464,224 patent/US11485724B2/en active Active
- 2017-11-23 CA CA3049161A patent/CA3049161C/en active Active
- 2017-11-23 AU AU2017366514A patent/AU2017366514B2/en active Active
- 2017-11-23 CA CA3045703A patent/CA3045703C/en active Active
- 2017-11-23 AU AU2017366515A patent/AU2017366515B2/en active Active
- 2017-11-23 JP JP2019528110A patent/JP7143295B2/ja active Active
- 2017-11-23 US US16/464,228 patent/US20220372013A2/en active Pending
- 2017-11-23 CN CN201711185728.6A patent/CN108101887A/zh active Pending
- 2017-11-23 EP EP17873820.9A patent/EP3546449A4/en active Pending
- 2017-11-23 WO PCT/CN2017/112669 patent/WO2018095378A1/zh not_active Ceased
- 2017-11-23 CN CN201711184758.5A patent/CN108101886A/zh active Pending
- 2017-11-23 JP JP2019528114A patent/JP7143296B2/ja active Active
-
2022
- 2022-06-03 US US17/832,518 patent/US11873287B2/en active Active
-
2023
- 2023-12-08 US US18/533,755 patent/US12331030B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002070480A1 (es) | 2001-03-01 | 2002-09-12 | Fundacion Universitaria San Pablo Ceu | Derivados de glutarimida como agentes terapeuticos |
| JP4703554B2 (ja) | 2003-03-27 | 2011-06-15 | 天津和美生物技術有限公司 | 水溶性のサリドマイド誘導体 |
| JP2008534631A (ja) | 2005-04-07 | 2008-08-28 | 天津和美生物技▲術▼有限公司 | 細胞の腫瘍壊死因子釈放を抑制できるピペリジン−２，６−−ジオン誘導物 |
| CN1961876A (zh) | 2005-11-08 | 2007-05-16 | 北京恩华医药研究院 | 邻苯二甲酰亚胺衍生物在制备抗新血管生成的药物中的用途 |
| JP2013535009A (ja) | 2010-06-18 | 2013-09-09 | 大鵬薬品工業株式会社 | Ｐｒｐｋ−ｔｐｒｋｂモジュレーター及びその使用 |
| JP2020500205A (ja) | 2016-11-24 | 2020-01-09 | 天津和美生物技術有限公司 | ピペリジン−２，６−ジオン誘導体及び潰瘍性結腸炎の治療 |
Non-Patent Citations (1)
| Title |
|---|
| International Journal of Nanomedicine，2011年，No.6，pp.2007-2021 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017366514B2 (en) | 2021-01-21 |
| CA3045703C (en) | 2021-11-02 |
| US11873287B2 (en) | 2024-01-16 |
| JP2020500205A (ja) | 2020-01-09 |
| CA3049161A1 (en) | 2018-05-31 |
| CA3045703A1 (en) | 2018-05-31 |
| US12331030B2 (en) | 2025-06-17 |
| US20220372013A2 (en) | 2022-11-24 |
| JP2020500204A (ja) | 2020-01-09 |
| US20190352277A1 (en) | 2019-11-21 |
| CN108101886A (zh) | 2018-06-01 |
| AU2017366515A1 (en) | 2019-06-13 |
| WO2018095378A1 (zh) | 2018-05-31 |
| EP3546449A1 (en) | 2019-10-02 |
| EP3546449A4 (en) | 2020-06-10 |
| EP3546450A1 (en) | 2019-10-02 |
| US20220306600A1 (en) | 2022-09-29 |
| WO2018095377A1 (zh) | 2018-05-31 |
| US11485724B2 (en) | 2022-11-01 |
| CA3049161C (en) | 2023-03-07 |
| AU2017366515B2 (en) | 2021-01-21 |
| AU2017366514A1 (en) | 2019-06-13 |
| JP7143296B2 (ja) | 2022-09-28 |
| US20240132466A1 (en) | 2024-04-25 |
| CN108101887A (zh) | 2018-06-01 |
| EP3546450A4 (en) | 2020-06-10 |
| US20190389835A1 (en) | 2019-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7143296B2 (ja) | ピペリジン－２，６－ジオン誘導体及び潰瘍性結腸炎の治療 | |
| CN115515944A (zh) | 苯并噻唑类衍生物及其用途 | |
| CN112638866A (zh) | 索拉非尼衍生物的共晶体及其制备方法 | |
| US11767295B2 (en) | Isoindole derivative | |
| US9907792B2 (en) | Acetic acid ester compound or salt thereof | |
| US11639332B2 (en) | Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases | |
| HK40107092A (en) | Dhodh inhibitors containing a carboxylic acid bioisostere | |
| CN106946851B (zh) | 一种用于预防和治疗肾结石的药物 | |
| HK40079290A (en) | Benzothiazole derivative and application thereof | |
| HK40050156A (en) | Co-crystal of sorafenib derivatives and process for preparation thereof | |
| JPS62283924A (ja) | 循環器疾患治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200709 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200709 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20200721 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210520 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210525 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210825 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211004 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20211005 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211221 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220318 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220520 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220823 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220914 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7143295 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |